Rhabdomyosarcoma

Stephen X Skapek, Andrea Ferrari, Abha A. Gupta, Philip J. Lupo, Erin Butler, Janet Shipley, Frederic G. Barr, Douglas S. Hawkins

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and represents a high-grade neoplasm of skeletal myoblast-like cells. Decades of clinical and basic research have gradually improved our understanding of the pathophysiology of RMS and helped to optimize clinical care. The two major subtypes of RMS, originally characterized on the basis of light microscopic features, are driven by fundamentally different molecular mechanisms and pose distinct clinical challenges. Curative therapy depends on control of the primary tumour, which can arise at many distinct anatomical sites, as well as controlling disseminated disease that is known or assumed to be present in every case. Sophisticated risk stratification for children with RMS incorporates various clinical, pathological and molecular features, and that information is used to guide the application of multifaceted therapy. Such therapy has historically included cytotoxic chemotherapy as well as surgery, ionizing radiation or both. This Primer describes our current understanding of RMS epidemiology, disease susceptibility factors, disease mechanisms and elements of clinical care, including diagnostics, risk-based care of newly diagnosed and relapsed disease and the prevention and management of late effects in survivors. We also outline potential opportunities to further translate new biological insights into improved clinical outcomes.

Original languageEnglish (US)
Article number1
JournalNature Reviews Disease Primers
Volume5
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Rhabdomyosarcoma
Skeletal Myoblasts
Disease Susceptibility
Disease Management
Ionizing Radiation
Sarcoma
Neoplasms
Epidemiology
Therapeutics
Light
Drug Therapy
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Skapek, S. X., Ferrari, A., Gupta, A. A., Lupo, P. J., Butler, E., Shipley, J., ... Hawkins, D. S. (2019). Rhabdomyosarcoma. Nature Reviews Disease Primers, 5(1), [1]. https://doi.org/10.1038/s41572-018-0051-2

Rhabdomyosarcoma. / Skapek, Stephen X; Ferrari, Andrea; Gupta, Abha A.; Lupo, Philip J.; Butler, Erin; Shipley, Janet; Barr, Frederic G.; Hawkins, Douglas S.

In: Nature Reviews Disease Primers, Vol. 5, No. 1, 1, 01.12.2019.

Research output: Contribution to journalReview article

Skapek, SX, Ferrari, A, Gupta, AA, Lupo, PJ, Butler, E, Shipley, J, Barr, FG & Hawkins, DS 2019, 'Rhabdomyosarcoma', Nature Reviews Disease Primers, vol. 5, no. 1, 1. https://doi.org/10.1038/s41572-018-0051-2
Skapek SX, Ferrari A, Gupta AA, Lupo PJ, Butler E, Shipley J et al. Rhabdomyosarcoma. Nature Reviews Disease Primers. 2019 Dec 1;5(1). 1. https://doi.org/10.1038/s41572-018-0051-2
Skapek, Stephen X ; Ferrari, Andrea ; Gupta, Abha A. ; Lupo, Philip J. ; Butler, Erin ; Shipley, Janet ; Barr, Frederic G. ; Hawkins, Douglas S. / Rhabdomyosarcoma. In: Nature Reviews Disease Primers. 2019 ; Vol. 5, No. 1.
@article{f403a624d7134e43aec31efc8d2336e8,
title = "Rhabdomyosarcoma",
abstract = "Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and represents a high-grade neoplasm of skeletal myoblast-like cells. Decades of clinical and basic research have gradually improved our understanding of the pathophysiology of RMS and helped to optimize clinical care. The two major subtypes of RMS, originally characterized on the basis of light microscopic features, are driven by fundamentally different molecular mechanisms and pose distinct clinical challenges. Curative therapy depends on control of the primary tumour, which can arise at many distinct anatomical sites, as well as controlling disseminated disease that is known or assumed to be present in every case. Sophisticated risk stratification for children with RMS incorporates various clinical, pathological and molecular features, and that information is used to guide the application of multifaceted therapy. Such therapy has historically included cytotoxic chemotherapy as well as surgery, ionizing radiation or both. This Primer describes our current understanding of RMS epidemiology, disease susceptibility factors, disease mechanisms and elements of clinical care, including diagnostics, risk-based care of newly diagnosed and relapsed disease and the prevention and management of late effects in survivors. We also outline potential opportunities to further translate new biological insights into improved clinical outcomes.",
author = "Skapek, {Stephen X} and Andrea Ferrari and Gupta, {Abha A.} and Lupo, {Philip J.} and Erin Butler and Janet Shipley and Barr, {Frederic G.} and Hawkins, {Douglas S.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41572-018-0051-2",
language = "English (US)",
volume = "5",
journal = "Nature Reviews Disease Primers",
issn = "2056-676X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Rhabdomyosarcoma

AU - Skapek, Stephen X

AU - Ferrari, Andrea

AU - Gupta, Abha A.

AU - Lupo, Philip J.

AU - Butler, Erin

AU - Shipley, Janet

AU - Barr, Frederic G.

AU - Hawkins, Douglas S.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and represents a high-grade neoplasm of skeletal myoblast-like cells. Decades of clinical and basic research have gradually improved our understanding of the pathophysiology of RMS and helped to optimize clinical care. The two major subtypes of RMS, originally characterized on the basis of light microscopic features, are driven by fundamentally different molecular mechanisms and pose distinct clinical challenges. Curative therapy depends on control of the primary tumour, which can arise at many distinct anatomical sites, as well as controlling disseminated disease that is known or assumed to be present in every case. Sophisticated risk stratification for children with RMS incorporates various clinical, pathological and molecular features, and that information is used to guide the application of multifaceted therapy. Such therapy has historically included cytotoxic chemotherapy as well as surgery, ionizing radiation or both. This Primer describes our current understanding of RMS epidemiology, disease susceptibility factors, disease mechanisms and elements of clinical care, including diagnostics, risk-based care of newly diagnosed and relapsed disease and the prevention and management of late effects in survivors. We also outline potential opportunities to further translate new biological insights into improved clinical outcomes.

AB - Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and represents a high-grade neoplasm of skeletal myoblast-like cells. Decades of clinical and basic research have gradually improved our understanding of the pathophysiology of RMS and helped to optimize clinical care. The two major subtypes of RMS, originally characterized on the basis of light microscopic features, are driven by fundamentally different molecular mechanisms and pose distinct clinical challenges. Curative therapy depends on control of the primary tumour, which can arise at many distinct anatomical sites, as well as controlling disseminated disease that is known or assumed to be present in every case. Sophisticated risk stratification for children with RMS incorporates various clinical, pathological and molecular features, and that information is used to guide the application of multifaceted therapy. Such therapy has historically included cytotoxic chemotherapy as well as surgery, ionizing radiation or both. This Primer describes our current understanding of RMS epidemiology, disease susceptibility factors, disease mechanisms and elements of clinical care, including diagnostics, risk-based care of newly diagnosed and relapsed disease and the prevention and management of late effects in survivors. We also outline potential opportunities to further translate new biological insights into improved clinical outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85059768053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059768053&partnerID=8YFLogxK

U2 - 10.1038/s41572-018-0051-2

DO - 10.1038/s41572-018-0051-2

M3 - Review article

VL - 5

JO - Nature Reviews Disease Primers

JF - Nature Reviews Disease Primers

SN - 2056-676X

IS - 1

M1 - 1

ER -